Evercore ISI Group Initiates Coverage On Erasca with Outperform Rating, Announces Price Target of $45
Evercore ISI Group analyst Josh Schimmer initiates coverage on Erasca (NASDAQ:ERAS) with a Outperform rating and announces Price Target of $45.
Stocks That Hit 52-Week Highs On Tuesday
Before 10 a.m. ET on Tuesday, 100 stocks hit new 52-week highs.
Morgan Stanley Initiates Coverage On Erasca with Equal-Weight Rating, Announces Price Target of $25
Morgan Stanley analyst Jeffrey Hung initiates coverage on Erasca (NASDAQ:ERAS) with a Equal-Weight rating and announces Price Target of $25.
B of A Securities Initiates Coverage On Erasca with Buy Rating, Announces Price Target of $28
B of A Securities initiates coverage on Erasca (NASDAQ:ERAS) with a Buy rating and announces Price Target of $28.
Guggenheim Initiates Coverage On Erasca with Buy Rating, Announces Price Target of $25
Guggenheim analyst Michael Schmidt initiates coverage on Erasca (NASDAQ:ERAS) with a Buy rating and announces Price Target of $25.
JP Morgan Initiates Coverage On Erasca with Overweight Rating, Announces Price Target of $28
JP Morgan analyst Anupam Rama initiates coverage on Erasca (NASDAQ:ERAS) with a Overweight rating and announces Price Target of $28.
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week.
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 5)
Stocks That Hit 52-Week Highs On Thursday
On Thursday morning, 159 companies achieved new highs for the year.